DIAGNOSIS OF HIV AND OTHER SEXUALLY TRANSMITTED DISEASES (STDS) IN HIGH-RISK POPULATION (MEN WHO HAVE SEX WITH MEN WHO USE CHEMSEX)
Men who have sex with men (MSM) participating in Chemsex is a group identified at high risk of HIV infection in Catalonia and Spain. There is a need for a focused effort in the prevention of HIV transmission and other STDs. Detecting the prevalence of Chemsex in this area and performing rapid HIV tests systematically in this population could increase the number of new HIV diagnoses and lead to earlier treatment.
The design of this project is a single centre, prospective cohort study. Patients will be assessed for Chemsex using a validated questionnaire. Users of Chemsex will be assessed every three months for HIV and other STDs. The sample includes an estimated 1610 patients during the first year. This includes 410 from ER, 600 from PEP clinic, 300 from an STD clinic and 300 from an NGO. The post program 2-year monitoring phase is expected to engage over 1000 patients.
- To identify the prevalence of the use of Chemsex.
- Provide diagnostic screenings of HIV and other STDs in this high-risk population.
- To train health workers at the hospital in non-HIV-Infectious Diseases areas and local NGO in Chemsex and HIV-STD signs and symptoms, in order to suspect this high-risk population and contact the HIV Unit.
High prevalence of unprotected sexual risk practices, poly drug use and slamming are found in our MSM Chemsex users cohort. The prevalence of HCV and other asymptomatic STDs is very common in this population. Specific risk reduction strategies are necessary in this population.
Dr. Joseph Mallolas
The Hospital Clínic
Jun 2018 – Mar 2021
Retention in Care and Adherence
Key study materials
This study is the first attempt to implement the distribution of HIV Home-based Self-Testing (HIVST) within an emergency medicine setting to increase the coverage of HIV screening and the subsequent linkage to care of PLHIV in Jamaica.
The First "90": Feasibility and Acceptability of Implementing Training and Development to Support Successful Adoption of Opt Out HIV Testing in the Emergency and Acute Medical Settings in a Suburban Centre
In an effort to increase early diagnosis of HIV and improve linkage to care, this project evaluates the impact of a comprehensive training package to support opt out HIV testing.
The Use of Patient Reported Outcomes to Increase Viral Suppression Among Latino MSM in the United States
This study investigates barriers and facilitators specifically among foreign and US born Spanish and English-speaking Latino MSM.
NP-GBL-HVU-WCNT- 210042 | March 2022
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.